Resultados de la búsqueda 271-280 of 9976 for Peroxisome
To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by ...
Cancer. Quarterly eNewsletter that focuses on trends and advances in hematology and oncology at Mayo Clinic · Cardiovascular · Clinical Updates · Digestive ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
The purpose of this study is to further characterize the serum and Cerebral Spinal Fluid (CSF) biomarker profile of idiopathic normal pressure hydrocephalus, ...
The primary purpose of this study is to create a Mayo Clinic repository for neurodegenerative disorders such as Parkinson's disease (PD), ...
The goal of this research is to investigate the hypothesis that this presentation represents a spatially limited form of CNS inflammatory demyelinating disease.
In this study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's ...
The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 ...
We aim to determine whether cognitive impairment attributable to cerebral hemodynamic impairment in patients with high-grade asymptomatic carotid artery ...
Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and may reduce harm to normal cells. Lutetium Lu 177 dotatate ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?